ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC - 100459

Spotlight
Video

ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC

moasc has 295 videos Subscribe Here

Loading........
Description: Viola Zhu, MD, PhD of UC Irvine Health gives an overview of the ARCHER 1050 trial in EGFR+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.

Abstract LBA9007: ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC at the First Line Setting
Shared By : moasc
Posted on : 08/02/17
Added : 9 months ago